Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781291 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP2C19PRKG1SPHK1SMN1; SMN2 | |
| SCHEMBL24976319 | 0.91 | NOTUM (0.43) | CYP1A2CYP2C19PRKG1SMN1; SMN2CD274 | |
| SCHEMBL1817183 | 0.86 | CYP1A2 (0.51) | CYP1A2CYP2C19SPHK1SMN1; SMN2CD274 | |
| SCHEMBL2032294 | 0.86 | CYP1A2 (0.51) | CYP1A2CYP2C19SPHK1SMN1; SMN2CD274 | |
| SCHEMBL3148407 | 0.86 | CYP1A2 (0.51) | CYP1A2CYP2C19SPHK1SMN1; SMN2CD274 | |
| SCHEMBL3148367 | 0.86 | NPBWR1 (0.53) | CYP1A2SPHK1CD274PDCD1SLC6A9 | |
| SCHEMBL2030130 | 0.86 | NPBWR1 (0.53) | CYP1A2SPHK1CD274PDCD1SLC6A9 | |
| SCHEMBL1815987 | 0.86 | NPBWR1 (0.53) | CYP1A2SPHK1CD274PDCD1SLC6A9 | |
| SCHEMBL7790236 | 0.83 | KDM4E (0.47) | PRKG1SMN1; SMN2CD274PDCD1 | |
| SCHEMBL7790240 | 0.83 | KDM4E (0.47) | PRKG1SMN1; SMN2CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010056185-A1 | C3A receptor ligands | LEE DENNIS (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1017664-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015490-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056185-A1 | C3A receptor ligands | C3AR1, C5AR1, C5AR2 | CYP1A2 3030/4885CYP2C19 3720/4885PRKG1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.